12/21
07:51 am
atra
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
Medium
Report
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
12/20
08:19 am
atra
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $25.00 price target on the stock.
High
Report
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $25.00 price target on the stock.
12/7
12:40 pm
atra
Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Positive Post-Trans
Medium
Report
Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Positive Post-Trans
11/30
07:10 am
atra
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was upgraded by analysts at TD Cowen to a "strong-buy" rating.
Medium
Report
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was upgraded by analysts at TD Cowen to a "strong-buy" rating.
11/27
04:01 pm
atra
Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference
Low
Report
Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference
11/15
07:30 am
atra
Atara Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Medium
Report
Atara Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/13
04:01 pm
atra
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference
High
Report
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference
11/13
08:28 am
atra
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $13.00 to $21.00. They now have a "buy" rating on the stock.
High
Report
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $13.00 to $21.00. They now have a "buy" rating on the stock.
11/12
07:04 pm
atra
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
High
Report
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/12
04:41 pm
atra
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress [Yahoo! Finance]
High
Report
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress [Yahoo! Finance]
11/12
04:01 pm
atra
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress
High
Report
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress
11/5
04:01 pm
atra
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Low
Report
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
10/16
05:53 am
atra
Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies [Yahoo! Finance]
Medium
Report
Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies [Yahoo! Finance]
10/15
01:45 pm
atra
Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
Low
Report
Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
10/4
04:01 pm
atra
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)